quarta-feira, 7 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 17, 2026

This Will Be McDonald’s Stock Price Next Year

View original at finance.yahoo.com
This Will Be McDonald’s Stock Price Next Year Quick Read McDonald’s (MCD) achieved Q4 2025 revenue of $7B (up 9.7% year-over-year) and EPS of $3.12, beating estimates, while its loyalty platform scaled to 210 million active users generating approximately $37B in annual sales and driving 6.8% U.S…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • McDonald's executed a V-shaped recovery through 2025, its loyalty platform is scaling rapidly, and valuation remains reasonable for a franchise-dominant, cash-generating business of this quality

    60% confidence
  • Loyalty program is approaching 250 million users

    60% confidence
  • McDonald's stock price target is $342, implying 9.7% upside over the next 12 months

    60% confidence
  • McDonald's plans 2,600 new restaurant openings globally in 2026 to drive 2.5% systemwide sales growth

    60% confidence
  • 24/7 Wall St. recommendation is buy with a 90% confidence level

    60% confidence
  • The risk-reward tilts constructively for patient investors based on comp sales acceleration, loyalty program scaling to $37 billion in annual sales, and continued restaurant expansion in 2026

    60% confidence

Data points we hold from this source

McDonald's Corporation · stock return ytd0.77 percent
McDonald's Corporation · stock return 1y0.28 percent
McDonald's Corporation · comparable sales growth global5.7 percent
McDonald's Corporation · eps3.12 USD
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
A nossa leitura dos dados ›
Sinais que acompanhamos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,985
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,985 factos verificados com a fonte5,351 documentos-fonte arquivados
Consulte estes dados → isubstrate.com